DCF Valuation Model for Invex Therapeutics, page-82

Very interesting reads Jelly - appreciate the share, I have highlighted a key points here regarding future projections.

Looks like 6-8 makes most sense, with many doctors diagnosing obese women with headaches prematurely, alongside a myriad of other misdiagnosis for one reason or another fuelling the recent explosion of IIH incidence rates. I would assume that this is curved over the coming decade, with a better framework for ensuring correct diagnosis and incidence rate to therefore plateau.

Will stick to 6-8 as a maximum, growing at ~3% alongside population growth, and a further growth rate multiplier for growth in obesity numbers over the course of the DCF timeline.